BioCentury | Nov 7, 2020
Politics, Policy & Law

CIRM refuels with $5.5B and a chance to improve its track record

...of funding 92 clinical trials and 2,900 “medical discoveries”...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Nov 21, 2018
Preclinical News

Gene recombination sheds light on Alzheimer's failures, suggests HIV drugs could help

A new understanding of amyloid precursor protein (APP) variants from researchers at Sanford Burnham Prebys Medical Discovery Institute and University of California San Diego could help explain why Alzheimer's disease candidates targeting the amyloid pathway...
BioCentury | Apr 24, 2018
Company News

Reed replacing Zerhouni at Sanofi

Head of Global R&D Elias Zerhouni will retire from Sanofi (Euronext:SAN; NYSE:SNY), effective June 30. He has held the post since 2011. John Reed will succeed Zerhouni. This month, Reed stepped down as head of...
BioCentury | Mar 8, 2018
Company News

Reed leaving Roche's pRED division

Roche (SIX:ROG; OTCQX:RHHBY) said John Reed, the head of its Pharma Research and Early Development unit, is leaving the company for "personal reasons" and returning to the U.S., effective April 2. William Pao, global head...
BioCentury | Feb 28, 2018
Company News

Sanford Burnham returns $12M to Florida before departure

Sanford Burnham Prebys Medical Discovery Institute agreed to return $12.3 million to the state of Florida as the institute prepares to wind down operations at its Florida campus. Sanford Burnham first announced its plans to...
BioCentury | Jan 31, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles; peptides Silicon-based nanoparticles linked to bacteria-targeting peptides could help deliver antibiotics to treat bacterial infections. Generation of the pathogen-specific nanoparticles involves screening a peptide library in vitro and in mouse-based bacteria binding assays...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Patient sample and mouse studies suggest promoting the interaction of SORL1 with EPHA4 could help treat AD. In frontal cortical tissue samples from postmortem patients, levels of activated EPHA4 -- a...
Items per page:
1 - 10 of 77
BioCentury | Nov 7, 2020
Politics, Policy & Law

CIRM refuels with $5.5B and a chance to improve its track record

...of funding 92 clinical trials and 2,900 “medical discoveries”...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Nov 21, 2018
Preclinical News

Gene recombination sheds light on Alzheimer's failures, suggests HIV drugs could help

A new understanding of amyloid precursor protein (APP) variants from researchers at Sanford Burnham Prebys Medical Discovery Institute and University of California San Diego could help explain why Alzheimer's disease candidates targeting the amyloid pathway...
BioCentury | Apr 24, 2018
Company News

Reed replacing Zerhouni at Sanofi

Head of Global R&D Elias Zerhouni will retire from Sanofi (Euronext:SAN; NYSE:SNY), effective June 30. He has held the post since 2011. John Reed will succeed Zerhouni. This month, Reed stepped down as head of...
BioCentury | Mar 8, 2018
Company News

Reed leaving Roche's pRED division

Roche (SIX:ROG; OTCQX:RHHBY) said John Reed, the head of its Pharma Research and Early Development unit, is leaving the company for "personal reasons" and returning to the U.S., effective April 2. William Pao, global head...
BioCentury | Feb 28, 2018
Company News

Sanford Burnham returns $12M to Florida before departure

Sanford Burnham Prebys Medical Discovery Institute agreed to return $12.3 million to the state of Florida as the institute prepares to wind down operations at its Florida campus. Sanford Burnham first announced its plans to...
BioCentury | Jan 31, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles; peptides Silicon-based nanoparticles linked to bacteria-targeting peptides could help deliver antibiotics to treat bacterial infections. Generation of the pathogen-specific nanoparticles involves screening a peptide library in vitro and in mouse-based bacteria binding assays...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Patient sample and mouse studies suggest promoting the interaction of SORL1 with EPHA4 could help treat AD. In frontal cortical tissue samples from postmortem patients, levels of activated EPHA4 -- a...
Items per page:
1 - 10 of 77